Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the level of cytokines (which are small proteins
important in cell signalling) in eye fluid (aqueous humour) in patients with wet age related
macular degeneration patients who have been treated with an injection in the eye
(intravitreal injection) with a drug called ranibizumab. The level of cytokines will be
compared between patients who have a good response to ranibizumab treatment and patients who
are non-responsive to ranibizumab and need other forms of therapy. This knowledge will help
for the future treatment and to potentially develop new medication for wet age-related
macular degeneration.